1. Xiutang is affiliated to Xiuzhen Pharmaceutical Group Marketing Co., Ltd., which is the 13th division of Xiuzhen Pharmaceutical. Xiuzhengtang is a direct sales store of Xiuzheng Pharmaceutical, and its products are mainly Xiuzheng Pharmaceutical. Revision Pharmaceutical Group (hereinafter referred to as Revision Pharmaceutical) is a large-scale modern private enterprise integrating scientific research, production and marketing, with its headquarters in Changchun and its marketing headquarters in Beijing. The industrial layout has extended from Tonghua, a famous medical city, to Liuhe, Shuangyang, Changchun, Beijing, Sichuan, Nanchang and other places. It covers a total area of 1.17 million square meters and a total construction area of 39, square meters. The Group has 66 wholly-owned subsidiaries with more than 8, employees and total assets of 7.5 billion yuan.
2. Xiulaigui, chairman of the board of directors, founded Xiulaigui in May 1995, is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing of Chinese patent medicines, chemical pharmaceuticals and biopharmaceuticals, drug chain management and standard cultivation of Chinese herbal medicines. Revision pharmaceutical industry has a development pattern of two head offices, three national-level well-known trademarks of "Revision, Tongyao and Starshu" and fourteen sales platforms. Since 2, it has ranked first in the comprehensive ranking of pharmaceutical enterprises in Jilin Province for 1 consecutive years, and ranked first in the profit ranking of Chinese medicine enterprises in China since 24, and its sales and profits rank among the top ten in China pharmaceutical industry. In 21, the output value was 16.9 billion yuan and the sales income was 17.1 billion yuan. From 2 to 21, the accumulated sales revenue was 55.22 billion yuan.